肿瘤细胞治疗研究
英文原题：Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors.
PD-1/PD-L1 抑制剂免疫治疗是新诊断的晚期或转移性 NSCLC 的标准治疗方法，可联合或不联合化疗。
PD-1/PD-L1抑制剂免疫疗法是新诊断晚期或转移性非小细胞肺癌（NSCLC）的标准治疗，无论是否联合化疗。然而，许多肿瘤会对这些免疫疗法产生耐药。对于转移性NSCLC患者，亟需开发二线及后续治疗中更有效的疗法。本综述概述正在研究用于治疗此类患者的新型免疫疗法，并总结评估这些疗法单药或与PD-1/PD-L1抑制剂联合使用的已完成及正在进行的临床试验。相关疗法包括免疫共刺激抗体、T细胞激动剂、溶瘤病毒、疫苗、TIL疗法和CAR-T疗法。
Immunotherapy with PD-1/PD-L1 inhibitors is the standard method of care for the treatment of newly diagnosed advanced or metastatic NSCLC, with or without chemotherapy. Many tumors, however, develop resistance to these immunotherapy agents. There is a need to develop more effective therapies for patients with metastatic NSCLC in the second-line setting and beyond. In this review, we present an overview of novel immunotherapies being investigated regarding the treatment of these patients. We summarize completed, as well as ongoing, trials investigating these therapies as monotherapy or in combination with PD-1/PD-L1 inhibitors. These include immune co-stimulatory antibodies, T-cell agonists, oncolytic viruses, vaccines, TIL therapies, and CAR-T therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
